EDIT vs LMT · rev $32.3M vs P/E 20, rev $75.05B
Editas Medicine Inc (EDIT) versus Lockheed Martin Corporation (LMT) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Lockheed Martin Corporation (LMT) is a aerospace & defense company listed on US. It is led by Jim Taiclet.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported LMT revenue for 2025-12-31 was $75.05B. Net income was $5.02B. Revenue was up 5.6% from 2024-12-31 to 2025-12-31. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
EDIT currently screens at market cap $375.2M. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
Not investment advice. Open the EDIT and LMT stock pages for the full models.
Not investment advice.